Press

2024-03-20

Kancera announces the outcome of the company’s rights issue

The board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders and which was covered by subscription and guarantee commitments...

Read More
2024-03-01

Kancera publishes prospectus in connection with the company’s rights issue

Kancera AB (”Kancera” or the ”Company”) announced on February 23, 2024, that the board of directors has resolved to carry out a new issue of shares with preferential rights for existing shareholders in the Company, corresponding to approximately SEK...

Read More
2024-02-23

Kancera resolves on a rights issue of approximately SEK 121.9 million

The board of directors of Kancera AB (”Kancera” or the ”Company”), has today, based on the issue authorization from the annual general meeting held on May 25, 2023, resolved on a new share issue with preferential rights for the...

Read More
2024-02-23

Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study

In connection with the interim report for the fourth quarter 2023, Kancera AB (publ) today provides a general operational update and reports that the company has signed a license agreement with the University of Newcastle. Through this agreement, Kancera...

Read More
2024-02-23

Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 17,1 million (SEK 11,6 million). Operating income amounted to SEK -18,5 million (SEK -14,0...

Read More
2024-02-06

Kancera presents the statistical analysis of top line data from the FRACTAL study

Kancera AB (Kancera) has previously reported the initial top line results from the FRACTAL study and today Kancera presents the statistical analyses that confirm that: the primary objective was met, by showing that KAND567 was safe and well tolerated...

Read More
2023-12-20

Kancera reports positive top line results from the FRACTAL study

Kancera AB (publ) today reports the top line results from the FRACTAL study, a double-blinded placebo-controlled, explorative phase IIa study of Kancera’s fractalkine blocker KAND567 in high-risk ST-elevation myocardial infarction (STEMI) patients undergoing acute percutaneous coronary intervention (PCI). The...

Read More
2023-11-17

Kancera provides operational update in connection with release of financial interim report for third quarter 2023

In connection with the release of the financial interim report for the third quarter of 2023, Kancera AB (publ) provides an operational update regarding its fractalkine blockers KAN567 and KAND145, both in clinical stage. Further, the company reports that...

Read More
2023-11-17

Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the third quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 9,2 million (SEK 8,7 million). Operating income for the third quarter amounted to SEK...

Read More
2023-10-23

Kancera reports that the phase I study of KAND145 has received regulatory approval

Kancera AB (publ) today reports that the Finnish regulatory agency (FIMEA) has approved Kancera’s application to conduct a phase I study of KAND145, the company’s second generation fractalkine blocking candidate drug.

Read More